MCID: ACT073
MIFTS: 62

Acute Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Acute Leukemia

MalaCards integrated aliases for Acute Leukemia:

Name: Acute Leukemia 39 12 30 56 15 17 74
Acute Undifferentiated Leukemia 74
Undifferentiated Leukemia 74
Stem Cell Leukaemia 12
Stem Cell Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12603
ICD9CM 36 208.0
NCIt 51 C9300
SNOMED-CT 69 24072005 91855006
ICD10 34 C95.0 C95.00

Summaries for Acute Leukemia

Disease Ontology : 12 A leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity. These lymphocytes (acute lymphocytic leukemia [ALL]) or myeloid cells (acute myelocytic leukemia [AML]) proliferate abnormally, replacing normal marrow tissue and hematopoietic cells and inducing anemia, thrombocytopenia, and granulocytopenia.

MalaCards based summary : Acute Leukemia, also known as acute undifferentiated leukemia, is related to megakaryocytic leukemia and childhood leukemia. An important gene associated with Acute Leukemia is BAALC (BAALC Binder Of MAP3K1 And KLF4), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Arsenic trioxide and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are no effect and Reduced mammosphere formation

Wikipedia : 77 Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original... more...

Related Diseases for Acute Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Acute Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 454, show less)
# Related Disease Score Top Affiliating Genes
1 megakaryocytic leukemia 32.5 JAK2 MPO RUNX1
2 childhood leukemia 32.5 ETV6 KMT2A MLLT3 MTHFR RUNX1
3 acute lymphocytic leukemia 32.4 CSF3 ETV6 GSTM1 MTHFR RUNX1
4 lymphoblastic lymphoma 32.3 DNTT KMT2A MPO
5 leukemia, acute lymphoblastic 32.3 AFF1 ANPEP DNTT ETV6 FLT3 KMT2A
6 leukemia 32.2 BAALC CEBPA CREBBP ETV6 FLT3 JAK2
7 acute promyelocytic leukemia 32.0 ANPEP CD34 CEBPA CSF3 FLT3 MPO
8 lymphocytic leukemia 30.9 DNTT ETV6 KMT2A RUNX1
9 leukemia, acute myeloid 30.7 AFF1 ANPEP BAALC CD34 CEBPA CSF3
10 myeloid leukemia 30.5 CEBPA CREBBP ETV6 FLT3 JAK2 KIT
11 lymphoid leukemia 30.3 ETV6 FLT3 JAK2 KMT2A
12 aplastic anemia 30.3 CD34 CSF3 FLT3 GSTM1
13 chronic myelomonocytic leukemia 30.2 ETV6 FLT3 JAK2 KIT RUNX1
14 myelodysplastic syndrome 30.2 ANPEP CD34 CEBPA CREBBP CSF3 DNTT
15 myeloma, multiple 30.1 CD34 CSF3 JAK2 KIT
16 8p11 myeloproliferative syndrome 30.0 FLT3 KIT RUNX1
17 chronic eosinophilic leukemia 29.9 FLT3 KIT WT1
18 cytogenetically normal acute myeloid leukemia 29.8 CEBPA FLT3 KMT2A WT1
19 acute erythroid leukemia 29.8 CEBPA JAK2
20 acute lymphoblastic leukemia, childhood 29.8 ETV6 GSTM1 MTHFR RUNX1
21 myeloid sarcoma 29.7 ANPEP DNTT FLT3 KIT KMT2A MPO
22 myelofibrosis 29.7 CD34 CSF3 FLT3 JAK2 KIT
23 lymphoma, non-hodgkin, familial 29.7 CD34 CSF3 DNTT JAK2
24 gastrointestinal stromal tumor 29.4 CD34 FLT3 KIT MTHFR
25 leukemia, chronic myeloid 28.9 CD34 CSF3 DNTT ETV6 FLT3 JAK2
26 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 28.7 CREBBP DNTT ETV6 FLT3 KIT KMT2A
27 precursor t-cell acute lymphoblastic leukemia 28.7 ANPEP CD34 DNTT ETV6 FLT3 KMT2A
28 bone marrow cancer 28.5 ANPEP CD34 CSF3 ETV6 FLT3 JAK2
29 acute leukemia of ambiguous lineage 12.4
30 chromosome 8p11 myeloproliferative syndrome 11.9
31 invasive aspergillosis 11.4
32 chronic leukemia 11.4
33 myeloproliferative neoplasm 11.4
34 myelodysplastic myeloproliferative cancer 11.1
35 severe congenital neutropenia 11.1
36 mthfr gene variant 11.1
37 hematopoietic stem cell transplantation 10.6
38 lymphoma 10.5
39 acute myeloid leukemia with t(9;11)(p22;q23) 10.5 KMT2A MLLT3
40 subacute myeloid leukemia 10.5 FLT3 JAK2
41 ring chromosome 21 10.5 ETV6 KMT2A
42 chromophobe renal cell carcinoma 10.5
43 renal oncocytoma 10.5
44 acute myeloblastic leukemia with maturation 10.5 FLT3 KIT
45 testicular gonadoblastoma 10.5 KIT WT1
46 b-cell childhood acute lymphoblastic leukemia 10.4 ETV6 RUNX1
47 acute myeloid leukemia with minimal differentiation 10.4 FLT3 MPO
48 nondisjunction 10.4 KIT MTHFR
49 blood coagulation disease 10.4 CSF3 JAK2 MTHFR
50 congenital mesoblastic nephroma 10.4 ETV6 KIT WT1
51 malignant mesenchymoma 10.4 ETV6 KIT WT1
52 graft-versus-host disease 10.3
53 blood platelet disease 10.3 CSF3 JAK2 RUNX1
54 sclerosing cholangitis, neonatal 10.3
55 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.3 CEBPA FLT3 KIT RUNX1
56 arteritic anterior ischemic optic neuropathy 10.3 GSTM1 MPO MTHFR
57 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.3
58 acute basophilic leukemia 10.3 ETV6 MPO
59 neonatal leukemia 10.3 AFF1 CREBBP FLT3 MLLT3
60 neutropenia 10.3
61 aspergillosis 10.3
62 candidiasis 10.3
63 myelophthisic anemia 10.2 ANPEP JAK2
64 down syndrome 10.2
65 gallbladder leiomyoma 10.2 CD34 KIT
66 lung leiomyosarcoma 10.2 CD34 KIT
67 liver leiomyoma 10.2 CD34 KIT
68 sarcoma 10.2
69 pneumonia 10.2
70 polycythemia 10.2
71 adult mesoblastic nephroma 10.2 CD34 ETV6
72 polycythemia vera 10.2
73 mast-cell sarcoma 10.2 ANPEP KIT MPO
74 deep leiomyoma 10.2 CD34 KIT
75 tetrasomy 21 10.2 ANPEP DNTT RUNX1
76 hypereosinophilic syndrome, idiopathic 10.2 KIT WT1
77 acute biphenotypic leukemia 10.2 DNTT KMT2A MPO
78 orbital granuloma 10.2 CD34 CSF3
79 extracutaneous mastocytoma 10.1 CD34 KIT
80 spondylocarpotarsal synostosis syndrome 10.1
81 hobnail hemangioma 10.1 CD34 WT1
82 trigonitis 10.1 CD34 CSF3
83 small intestine leiomyosarcoma 10.1 CD34 KIT
84 small intestinal sarcoma 10.1 CD34 KIT
85 leukemia, acute monocytic 10.1 CREBBP KMT2A MLLT3 MPO
86 wilms tumor 5 10.1
87 wilms tumor 6 10.1
88 granulocytopenia 10.1
89 adult fibrosarcoma 10.1 CD34 ETV6 WT1
90 peritoneal benign neoplasm 10.1 CD34 KIT WT1
91 diffuse peritoneal leiomyomatosis 10.1 CD34 KIT WT1
92 gallbladder sarcoma 10.1 CD34 KIT
93 spindle cell liposarcoma 10.1 CD34 KIT WT1
94 breast cancer 10.1
95 prostate leiomyosarcoma 10.1 CD34 KIT
96 muscle cancer 10.1 CD34 KIT WT1
97 pfeiffer syndrome 10.1
98 enterocolitis 10.1
99 thrombosis 10.1
100 disseminated intravascular coagulation 10.1
101 rhabdomyosarcoma 10.1
102 retina lymphoma 10.1 CD34 MPO
103 lymphoma, hodgkin, classic 10.0
104 hepatitis 10.0
105 hemosiderosis 10.0
106 mucormycosis 10.0
107 plexiform schwannoma 10.0 CD34 KIT
108 leukocyte disease 10.0 CD34 CSF3 KIT
109 burkitt lymphoma 10.0
110 essential thrombocythemia 10.0
111 lymphosarcoma 10.0
112 vascular cancer 10.0 ANPEP CD34 KIT
113 conventional fibrosarcoma 10.0 CD34 KIT
114 leukemia, chronic lymphocytic 2 10.0
115 leukemia, chronic lymphocytic 10.0
116 histiocytosis 10.0
117 chromosomal triplication 10.0
118 leukemia, b-cell, chronic 10.0
119 core binding factor acute myeloid leukemia 10.0 CEBPA CSF3 FLT3 JAK2 KIT RUNX1
120 pelger-huet anomaly 9.9
121 langerhans cell histiocytosis 9.9
122 arthritis 9.9
123 paroxysmal nocturnal hemoglobinuria 9.9
124 mucositis 9.9
125 lactic acidosis 9.9
126 pyoderma 9.9
127 hemoglobinuria 9.9
128 appendicitis 9.9
129 pyoderma gangrenosum 9.9
130 macroglobulinemia 9.9
131 chronic graft versus host disease 9.9
132 refractory anemia 9.9
133 pernicious anemia 9.9
134 retinoblastoma 9.9
135 thrombocytopenia 9.9
136 fusariosis 9.9
137 bacterial infectious disease 9.9
138 melanoma 9.9
139 pdgfrb-associated chronic eosinophilic leukemia 9.9
140 tetraploidy 9.9
141 chronic monocytic leukemia 9.9 CD34 MPO
142 wilms tumor 1 9.9
143 reticulum cell sarcoma 9.9
144 rhabdomyosarcoma 2 9.9
145 hemolytic anemia 9.9
146 small cell carcinoma 9.9
147 mumps 9.9
148 cardiac tamponade 9.9
149 patau syndrome 9.9
150 spindle cell sarcoma 9.9
151 sideroblastic anemia 9.9
152 bone marrow necrosis 9.9
153 germ cells tumors 9.9
154 venous hemangioma 9.8 CD34 WT1
155 atrial standstill 1 9.8
156 chediak-higashi syndrome 9.8
157 autoimmune lymphoproliferative syndrome, type v 9.8
158 severe combined immunodeficiency 9.8
159 endocarditis 9.8
160 respiratory failure 9.8
161 ecthyma 9.8
162 leukostasis 9.8
163 oral candidiasis 9.8
164 pericarditis 9.8
165 paraplegia 9.8
166 combined t cell and b cell immunodeficiency 9.8
167 influenza 9.8
168 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.8
169 diabetes insipidus 9.8
170 homologous wasting disease 9.8
171 depression 9.8
172 hypoxia 9.8
173 encephalopathy 9.8
174 hepatosplenic t-cell lymphoma 9.8
175 aleukemic leukemia cutis 9.8 ANPEP CD34 FLT3 MPO RUNX1
176 large intestine cancer 9.8 CD34 DNTT GSTM1 MTHFR
177 helix syndrome 9.7
178 priapism 9.7
179 autoimmune disease 9.7
180 multiple sclerosis 9.7
181 rheumatoid arthritis 9.7
182 thrombophilia due to thrombin defect 9.7
183 ataxia-telangiectasia 9.7
184 fanconi anemia, complementation group a 9.7
185 asthma 9.7
186 body mass index quantitative trait locus 1 9.7
187 protein z deficiency 9.7
188 infantile liver failure syndrome 1 9.7
189 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
190 cataract 9.7
191 diabetes mellitus 9.7
192 diffuse large b-cell lymphoma 9.7
193 hepatitis b 9.7
194 lymphedema 9.7
195 malignant glioma 9.7
196 mantle cell lymphoma 9.7
197 sinusitis 9.7
198 waldenstrom macroglobulinemia 9.7
199 hypophosphatemia 9.7
200 bone disease 9.7
201 cytomegalovirus retinitis 9.7
202 hypogonadotropic hypogonadism 9.7
203 hypopyon 9.7
204 pneumocystosis 9.7
205 telangiectasis 9.7
206 central nervous system leukemia 9.7
207 megaloblastic anemia 9.7
208 panniculitis 9.7
209 histoplasmosis 9.7
210 hepatitis c 9.7
211 hyperuricemia 9.7
212 thrombocytosis 9.7
213 testicular cancer 9.7
214 retinitis 9.7
215 hyperglycemia 9.7
216 juvenile xanthogranuloma 9.7
217 endophthalmitis 9.7
218 spindle cell hemangioma 9.7
219 lung oat cell carcinoma 9.7
220 cerebrovascular disease 9.7
221 juvenile rheumatoid arthritis 9.7
222 herpes simplex 9.7
223 malignant histiocytosis 9.7
224 measles 9.7
225 chickenpox 9.7
226 exophthalmos 9.7
227 meningitis 9.7
228 stomatitis 9.7
229 hypereosinophilic syndrome 9.7
230 acute graft versus host disease 9.7
231 acute respiratory distress syndrome 9.7
232 blastic plasmacytoid dendritic cell 9.7
233 dendritic cell tumor 9.7
234 glioma 9.7
235 heparin-induced thrombocytopenia 9.7
236 splenomegaly 9.7
237 headache 9.7
238 leukemia, acute lymphoblastic 3 9.6 AFF1 ANPEP DNTT ETV6 FLT3 KMT2A
239 ewing sarcoma 9.6 CD34 CSF3 DNTT KIT WT1
240 aryl hydrocarbon hydroxylase inducibility 9.6
241 biliary cirrhosis, primary, 1 9.6
242 gilbert syndrome 9.6
243 kabuki syndrome 1 9.6
244 systemic lupus erythematosus 9.6
245 meckel diverticulum 9.6
246 medulloblastoma 9.6
247 ataxia-pancytopenia syndrome 9.6
248 ovarian cancer 9.6
249 porphyria cutanea tarda 9.6
250 retinal detachment 9.6
251 small cell cancer of the lung 9.6
252 temporal arteritis 9.6
253 thrombocytopenic purpura, autoimmune 9.6
254 triiodothyronine receptor auxiliary protein 9.6
255 anemia, autoimmune hemolytic 9.6
256 autism 9.6
257 bloom syndrome 9.6
258 celiac disease 1 9.6
259 fanconi anemia, complementation group d2 9.6
260 hemolytic uremic syndrome, atypical 1 9.6
261 indifference to pain, congenital, autosomal recessive 9.6
262 lymphoblastic leukemia, acute, with lymphomatous features 9.6
263 neuroblastoma 1 9.6
264 neutrophil actin dysfunction 9.6
265 pyruvate kinase deficiency of red cells 9.6
266 rheumatic fever-related antigen 9.6
267 sjogren syndrome 9.6
268 insulin-like growth factor i 9.6
269 sarcoma, synovial 9.6
270 ataxia and polyneuropathy, adult-onset 9.6
271 budd-chiari syndrome 9.6
272 acute insulin response 9.6
273 sickle cell anemia 9.6
274 cervical cancer 9.6
275 aceruloplasminemia 9.6
276 polysubstance abuse 9.6
277 meningioma, familial 9.6
278 headache associated with sexual activity 9.6
279 neutrophilic dermatosis, acute febrile 9.6
280 avascular necrosis of femoral head, primary, 1 9.6
281 hepatitis c virus 9.6
282 chromosome 16p13.3 deletion syndrome, proximal 9.6
283 intraocular pressure quantitative trait locus 9.6
284 myxoid liposarcoma 9.6
285 hemorrhage, intracerebral 9.6
286 membranous nephropathy 9.6
287 human herpesvirus 8 9.6
288 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.6
289 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.6
290 deficiency anemia 9.6
291 acute liver failure 9.6
292 anaplastic large cell lymphoma 9.6
293 congestive heart failure 9.6
294 crohn's disease 9.6
295 hereditary hemorrhagic telangiectasia 9.6
296 osteonecrosis 9.6
297 primary biliary cirrhosis 9.6
298 spinal cord injury 9.6
299 systemic mastocytosis 9.6
300 thalassemia 9.6
301 chlamydia pneumonia 9.6
302 primary amebic meningoencephalitis 9.6
303 congenital hypothyroidism 9.6
304 foodborne botulism 9.6
305 hyperphosphatemia 9.6
306 infective endocarditis 9.6
307 interleukin-7 receptor alpha deficiency 9.6
308 immunoglobulin alpha deficiency 9.6
309 colitis 9.6
310 cardiac arrest 9.6
311 ectopic pregnancy 9.6
312 bacillary angiomatosis 9.6
313 nut midline carcinoma 9.6
314 lymphoproliferative syndrome 9.6
315 obstructive nephropathy 9.6
316 hepatic veno-occlusive disease 9.6
317 sensorineural hearing loss 9.6
318 osteomyelitis 9.6
319 prolymphocytic leukemia 9.6
320 meningoencephalitis 9.6
321 fanconi syndrome 9.6
322 discitis 9.6
323 brucellosis 9.6
324 hydronephrosis 9.6
325 chlamydia 9.6
326 tetanus 9.6
327 spinal meningioma 9.6
328 pulmonary edema 9.6
329 pyelonephritis 9.6
330 xanthogranulomatous pyelonephritis 9.6
331 diphtheria 9.6
332 hemopericardium 9.6
333 iron deficiency anemia 9.6
334 pericardial effusion 9.6
335 protein-energy malnutrition 9.6
336 cortical blindness 9.6
337 cryptococcosis 9.6
338 patulous eustachian tube 9.6
339 hemolytic-uremic syndrome 9.6
340 uveitis 9.6
341 pneumatosis cystoides intestinalis 9.6
342 diarrhea 9.6
343 porphyria 9.6
344 pure red-cell aplasia 9.6
345 facial paralysis 9.6
346 autoimmune polyendocrine syndrome 9.6
347 cerebral degeneration 9.6
348 hypothyroidism 9.6
349 echinococcosis 9.6
350 rheumatic fever 9.6
351 lymphadenitis 9.6
352 pneumothorax 9.6
353 cryptosporidiosis 9.6
354 squamous cell carcinoma 9.6
355 ocular melanoma 9.6
356 thyroid cancer 9.6
357 epilepsy 9.6
358 mononeuritis multiplex 9.6
359 malignant fibroxanthoma 9.6
360 gaucher's disease 9.6
361 cholecystitis 9.6
362 fallopian tube carcinoma 9.6
363 post-traumatic stress disorder 9.6
364 granulomatous hepatitis 9.6
365 hidradenitis 9.6
366 iron metabolism disease 9.6
367 macrocytic anemia 9.6
368 wernicke encephalopathy 9.6
369 testicular disease 9.6
370 splenic abscess 9.6
371 acute pancreatitis 9.6
372 astrocytoma 9.6
373 early myoclonic encephalopathy 9.6
374 lipid metabolism disorder 9.6
375 oligodendroglioma 9.6
376 embryonal rhabdomyosarcoma 9.6
377 ischemia 9.6
378 subacute leukemia 9.6
379 teratoma 9.6
380 purpura 9.6
381 liposarcoma 9.6
382 cellulitis 9.6
383 mastocytosis 9.6
384 choriocarcinoma 9.6
385 olfactory neuroblastoma 9.6
386 protein c deficiency 9.6
387 gastritis 9.6
388 tricuspid valve insufficiency 9.6
389 mutism 9.6
390 histiocytoma 9.6
391 erdheim-chester disease 9.6
392 fibrous histiocytoma 9.6
393 thyroid sarcoma 9.6
394 secretory meningioma 9.6
395 benign ependymoma 9.6
396 cerebellar astrocytoma 9.6
397 pancreatitis 9.6
398 ureteral obstruction 9.6
399 urinary tract obstruction 9.6
400 infertility 9.6
401 malignant teratoma 9.6
402 acute t cell leukemia 9.6
403 hypersplenism 9.6
404 connective tissue disease 9.6
405 monoclonal gammopathy of uncertain significance 9.6
406 muscular atrophy 9.6
407 septic arthritis 9.6
408 actinomycosis 9.6
409 herpes zoster 9.6
410 perinatal necrotizing enterocolitis 9.6
411 bacterial pneumonia 9.6
412 pyomyositis 9.6
413 rubella 9.6
414 lupus erythematosus 9.6
415 psoriasis 9.6
416 learning disability 9.6
417 amyloidosis 9.6
418 splenic tuberculosis 9.6
419 epiglottitis 9.6
420 cholangitis 9.6
421 hypoglycemia 9.6
422 hemophilia 9.6
423 triple x syndrome 9.6
424 rere-related disorders 9.6
425 al amyloidosis 9.6
426 anaplastic oligodendroglioma 9.6
427 carotidynia 9.6
428 cytomegalic inclusion disease 9.6
429 degos 'en cocarde' erythrokeratoderma 9.6
430 enterovesical fistula 9.6
431 ependymoma 9.6
432 glioblastoma 9.6
433 lipogranulomatosis 9.6
434 mycetoma 9.6
435 myelodysplastic syndrome with excess blasts 9.6
436 parainfluenza virus type 3 9.6
437 polymorphic reticulosis 9.6
438 primary biliary cholangitis 9.6
439 ring chromosome 1 9.6
440 stenotrophomonas maltophilia infection 9.6
441 triploidy 9.6
442 trisomy 22 9.6
443 undifferentiated pleomorphic sarcoma 9.6
444 weber syndrome 9.6
445 xp22.3 microdeletion syndrome 9.6
446 seizure disorder 9.6
447 cytomegalovirus infection 9.6
448 refractory anemia with excess blasts in transformation 9.6
449 xq12-q13.3 duplication syndrome 9.6
450 scedosporiosis 9.6
451 argyria 9.6
452 bullous pyoderma gangrenosum 9.6
453 osteoporotic fracture 9.6
454 hematologic cancer 9.1 CD34 CREBBP CSF3 DNTT ETV6 FLT3

Comorbidity relations with Acute Leukemia via Phenotypic Disease Network (PDN): (showing 2, show less)


Deficiency Anemia Neutropenia

Graphical network of the top 20 diseases related to Acute Leukemia:



Diseases related to Acute Leukemia

Symptoms & Phenotypes for Acute Leukemia

GenomeRNAi Phenotypes related to Acute Leukemia according to GeneCards Suite gene sharing:

27 (showing 2, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.26 AFF1 ANPEP BAALC CD34 CEBPA CREBBP
2 Reduced mammosphere formation GR00396-S 9.17 CD34 CEBPA CSF3 ETV6 GSTM1 KMT2A

MGI Mouse Phenotypes related to Acute Leukemia:

47 (showing 14, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 AFF1 ANPEP CD34 CEBPA CREBBP CSF3
2 immune system MP:0005387 10.34 AFF1 ANPEP CD34 CEBPA CREBBP CSF3
3 homeostasis/metabolism MP:0005376 10.3 CD34 CEBPA CREBBP DNTT ETV6 FLT3
4 growth/size/body region MP:0005378 10.27 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
5 cardiovascular system MP:0005385 10.24 ANPEP CEBPA CREBBP ETV6 KIT KMT2A
6 endocrine/exocrine gland MP:0005379 10.21 AFF1 ANPEP CEBPA CREBBP ETV6 FLT3
7 integument MP:0010771 10.14 ANPEP CD34 CEBPA CREBBP CSF3 ETV6
8 embryo MP:0005380 10.13 CREBBP ETV6 JAK2 KIT KMT2A MLLT3
9 mortality/aging MP:0010768 10.13 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
10 liver/biliary system MP:0005370 9.97 CEBPA CREBBP JAK2 KIT KMT2A MTHFR
11 neoplasm MP:0002006 9.9 CD34 CEBPA CREBBP ETV6 FLT3 JAK2
12 muscle MP:0005369 9.8 CEBPA CREBBP KIT KMT2A MPO STMN1
13 no phenotypic analysis MP:0003012 9.65 AFF1 CEBPA ETV6 FLT3 KIT KMT2A
14 normal MP:0002873 9.32 CEBPA CREBBP DNTT ETV6 JAK2 KIT

Drugs & Therapeutics for Acute Leukemia

Drugs for Acute Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 463, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 1327-53-3 518740
2
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
6
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
7
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
8
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
9
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123774-72-1, 83869-56-1
10
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
11
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
12
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24356-66-9 21704 32326
13
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
14
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
15
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 171228-49-2 147912
16
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 477468 3081921
17 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
21 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Liposomal amphotericin B Phase 4,Phase 3,Phase 2
25 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
26 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
27 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
32 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
37 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
40 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
42 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Thymoglobulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
51 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
52 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
53 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
54 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
55 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
56
Voriconazole Approved, Investigational Phase 3,Phase 2 137234-62-9 71616
57
Oprelvekin Approved, Investigational Phase 2, Phase 3 145941-26-0
58
Decitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 2353-33-5 451668
59
Daunorubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
60
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
61
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
62
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
63
Ofloxacin Approved Phase 3 82419-36-1 4583
64
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
65
Mercaptopurine Approved Phase 3,Phase 2,Phase 1,Not Applicable 50-44-2 667490
66
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
67
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
68
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
69
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
70
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
71
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
72
Thioguanine Approved Phase 3,Phase 2,Not Applicable 154-42-7 2723601
73
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
74
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
75
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
76
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
77
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
78
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 65271-80-9 4212
79
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 123318-82-1 119182
80
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
81
Idarubicin Approved Phase 3,Phase 1,Phase 2 58957-92-9 42890
82
Pegaspargase Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 130167-69-0
83
Iron Approved, Experimental Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
84
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
85
Tacrolimus Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 104987-11-3 6473866 445643 439492
86
Azacitidine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 320-67-2 9444
87
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 148-82-3 460612 4053
88
Carboplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
89 Clove Approved Phase 2, Phase 3
90
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
91
Hydroxyurea Approved Phase 3,Phase 2,Phase 1,Not Applicable 127-07-1 3657
92
Chlorambucil Approved Phase 3 305-03-3 2708
93
alemtuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 216503-57-0
94
Enalaprilat Approved Phase 3 76420-72-9 6917719
95
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5362032
96
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
97
Ichthammol Approved Phase 3,Phase 2,Phase 1 8029-68-3
98
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
99
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3,Not Applicable 437-38-7 3345
100
Dalteparin Approved Phase 3 9005-49-6
101
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 46507594 772